

K John Pasi MB ChB PhD FRCP FRCPATH FRCPCH

Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
Honorary Consultant Haematologist, The Royal London Hospital, Barts Health NHS Trust, London, UK

John Pasi is Professor of Haemostasis and Thrombosis at The Royal London Hospital, Barts and the London School of Medicine and Dentistry and Haemophilia Centre Director. Following his undergraduate medical degree and basic medical training, he undertook a PhD in Immunology and completed his training in haematology, specialising in haemostasis and thrombosis.

His clinical practice today spans both adults and children and covers all aspects of haemostasis and thrombosis. His research interests cover many aspects of inherited and acquired bleeding and clotting disorders, particularly new bioengineered therapies for haemophilia, novel therapies for haemophilia including gene therapy and RNAi technologies as well as the optimization of currently available therapies. He is closely involved in the design and development of clinical trials for new therapies and evolving phase 1-4 programmes. In addition, he has a major interest in the development of robust and harmonised outcome measures for haemophilia including application to research.

He has also been involved in the development of national policy and guideline formulation across a broad range of haemostatic and thrombotic disorders and the development of novel models for haematology training initiatives such as residential academies and preceptorships for both haemostasis and thrombosis. Previously he was an advisor to the Parliamentary Health Select Committee on Health working on VTE prevention in hospital and the subsequent national drive on introducing universal VTE risk assessment and treatment into hospital practice with the Department of Health, which has now been embedded in UK practice for a decade.

He currently chairs the London Haemophilia Clinical Advisory Group and Commissioning Forum, is a member of NHS England Clinical Reference Group (GRG)

for Inherited Bleeding Disorders, leads the link between the CRG and NIHR on research and co-chair of the ISTH Scientific and Standardization Committee on factor VIII, factor IX and rare coagulation disorders and the WFH Gene Therapy Roundtable.

Most recently he has been involved in the clinical response to Covid-19 infection and especially the thrombosis issues that are increasingly being recognised as a major part of the pathology of the disease. He is a member of the National Emergency Critical Care Committee advising on thrombosis issues and a member of the multidisciplinary working group on thrombosis. He is also part of a small UK group working with the REMAP-CAP global trial platform developing a research protocol for anticoagulation in Covid-19.